Investment Rating - The report indicates a cautious outlook for the pharmaceutical sector in 2024 and early 2025, with a strong focus on the innovative drug segment as a key investment opportunity [1][5]. Core Insights - The pharmaceutical sector is expected to face continued pressure on overall performance and profit margins due to factors such as healthcare payment environment, industry regulation, and changing consumer conditions in 2024 and Q1 2025 [1][18]. - Despite the challenges, there is optimism for a recovery in the pharmaceutical sector in the second half of 2025, driven by easing pressures from policies and fundamentals, leading to a potential turnaround in performance and stock prices [1][21]. - The innovative drug segment is highlighted as a primary focus for investment, with expectations for significant growth and valuation recovery for leading companies in this space [2][5]. Summary by Sections Pharmaceutical Sector Overview - The innovative drug segment is performing well, with leading companies like BeiGene and Hengrui Medicine showing strong revenue and business development (BD) income growth [2][22]. - The overall pharmaceutical sector is under pressure, with profit margins declining, except for the innovative drug segment which is experiencing independent growth [1][18]. Biopharmaceuticals - The biopharmaceutical sector is facing challenges, but there are opportunities for growth in specific areas such as long-acting interferons and insulin products, which are expected to see a turnaround [2][4]. Retail Pharmacy - The retail pharmacy sector is showing signs of marginal improvement, with expectations for a gradual return to normal growth in 2025 [2][4]. Medical Services and Aesthetic Medicine - The medical services and aesthetic medicine sectors are experiencing a mild recovery, with expectations for sustained performance in 2025 [3][4]. Traditional Chinese Medicine - The traditional Chinese medicine sector is expected to improve gradually throughout the year, following a challenging 2024 [4][12]. Medical Devices - The medical device sector is anticipated to recover gradually, with significant growth expected from overseas market expansion [4][12]. Investment Recommendations - The report emphasizes the importance of focusing on innovative drug opportunities throughout 2025, particularly in companies with strong international capabilities and those involved in business development [5][21].

Core Viewpoint - The company reported a mixed financial performance for 2024, with revenue growth but a decline in net profit, while the first quarter of 2025 shows signs of recovery in profitability [1][2][4]. Financial Performance Summary - For 2024, the company achieved a revenue of 26.497 billion yuan, with a net profit of 915 million yuan, reflecting year-on-year changes of +8.01% for revenue, -21.58% for net profit, and -22.42% for net profit excluding non-recurring items [1]. - In Q4 2024, revenue was 6.766 billion yuan, with a net profit of 57 million yuan, showing a year-on-year revenue decline of -0.63%, but significant increases in net profit of +820.48% and +240.71% for net profit excluding non-recurring items [1]. - For Q1 2025, revenue reached 6.956 billion yuan, with a net profit of 460 million yuan, indicating year-on-year growth of +3.02% for revenue and +15.45% for net profit [1]. Operational Strategy Summary - The company closed 733 stores in 2024 to optimize its store network, which is expected to improve profitability in the long run despite short-term revenue pressure [2]. - The performance of traditional Chinese and Western medicine segments remained stable, with revenue growth of +12.82% in 2024 and +5.80% in Q1 2025, while consumer products faced challenges with declines in revenue [2]. - The company is leveraging AI technology by integrating DeepSeek-R1's "AI Xiaosan" to enhance operational efficiency through improved customer service and analysis capabilities [2]. Expansion and Market Position Summary - The company continues to expand its store network, with a total of 16,622 stores as of Q1 2025, including 6,239 franchise stores, and a net increase of 2,479 stores in 2024 [3]. - Revenue from franchise and distribution business reached 3.940 billion yuan in 2024, growing by +15.12%, and 1.130 billion yuan in Q1 2025, growing by +25.34% [3]. - The company is making progress in establishing specialized pharmacy qualifications, with 248 DTP pharmacies and over 10,000 designated medical insurance stores by the end of 2024 [3]. Profit Forecast and Investment Outlook - The company is expected to see profit growth outpacing revenue growth in 2025, with projected net profits of 1.07 billion yuan, 1.23 billion yuan, and 1.40 billion yuan for 2025-2027, respectively [4]. - The company is anticipated to benefit from industry trends and network optimization, leading to improved performance and market share [4].

Core Viewpoint - The company reported a mixed performance in its 2024 annual report and 2025 Q1 report, with revenue growth but a decline in net profit for 2024, while Q1 2025 showed signs of recovery in net profit due to cost reduction and efficiency improvements [1][2]. Group 1: Financial Performance - In 2024, the company achieved revenue of 26.497 billion yuan and a net profit of 915 million yuan, representing a year-on-year growth of 8.01% in revenue but a decline of 21.58% in net profit [1][2]. - For Q1 2025, the company reported revenue of 6.956 billion yuan and a net profit of 460 million yuan, with revenue growth of 3.02% and a significant net profit increase of 15.45% year-on-year [1][2]. Group 2: Segment Performance - In 2024, the revenue breakdown showed that traditional Chinese and Western medicine generated 19.968 billion yuan (+12.82%), while Chinese medicinal materials and non-pharmaceuticals generated 2.945 billion yuan (-0.99%) and 2.948 billion yuan (-9.52%) respectively [2]. - For Q1 2025, the revenue from traditional Chinese and Western medicine was 5.324 billion yuan (+5.80%), while Chinese medicinal materials and non-pharmaceuticals generated 714 million yuan (-9.38%) and 709 million yuan (-8.04%) respectively [2]. Group 3: Operational Efficiency - The company has optimized its store operations and implemented cost reduction measures, leading to improved performance. As of Q1 2025, the company operated 16,622 stores, with 54 new self-built stores, 189 new franchise stores, and 174 closures [3]. - The company’s expense ratio decreased by 1.28 percentage points year-on-year in Q1 2025, indicating effective cost control and efficiency improvements [3]. Group 4: Investment Outlook - The company is projected to achieve net profits of 1.063 billion yuan, 1.197 billion yuan, and 1.349 billion yuan for the years 2025 to 2027, reflecting year-on-year growth rates of 16.2%, 12.7%, and 12.7% respectively [4]. - For 2025, the company is assigned a price-to-earnings ratio of 25, with an expected earnings per share of 0.93 yuan, leading to a target price of 23.25 yuan per share, and a buy-A investment rating is recommended [4].

Core Insights - The company reported a revenue of 26.497 billion yuan in 2024, an increase of 8.0% year-on-year, but a decline in net profit attributable to shareholders by 21.6% to 915 million yuan [1] - In Q1 2025, the company achieved a revenue of 6.956 billion yuan, a 3.0% increase year-on-year, with a net profit attributable to shareholders of 460 million yuan, up 15.5% [1] Operational Analysis - The company opened 907 self-built stores, acquired 420 stores, and added 1,885 franchise stores in 2024, while closing 733 stores, indicating a strategic optimization of its store network during an industry adjustment period [2] - In Q1 2025, the company net added 69 stores, including 54 new stores, 0 acquisitions, and 189 franchise stores, while closing 174 stores, bringing the total to 16,622 stores [2] - The fastest-growing segment in Q1 2025 was traditional Chinese and Western medicine, generating approximately 5.32 billion yuan in revenue, a year-on-year increase of 5.8% [2] - The company is focusing on expanding its presence in provincial markets, achieving a revenue growth of 10.7% in regions outside its primary market [2] Profit Forecast, Valuation, and Rating - Following the adjustment period in 2024, the company is expected to return to a normal growth trajectory, with projected net profits of 1.1 billion yuan, 1.32 billion yuan, and 1.52 billion yuan for 2025, 2026, and 2027, respectively, reflecting year-on-year growth rates of 20.1%, 19.8%, and 15.3% [3] - The estimated earnings per share (EPS) for 2025, 2026, and 2027 are projected to be 0.96 yuan, 1.16 yuan, and 1.33 yuan, respectively, with corresponding price-to-earnings (PE) ratios of 17, 15, and 13 times [3]

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-045 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于2025年第一季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所发布的上市公司分行业信息披露指引及《关于做好主 板上市公司 2025 年第一季度报告披露工作的主要提醒》相关要求，现将益丰 大药房连锁股份有限公司（以下简称"公司"）2025 年第一季度主要经营数据披 露如下： 一、报告期末主要经营数据 | | | 主营业务分行业情况 | | | | | | --- | --- | --- | --- | --- | --- | --- | | | | | 毛利率 | 营业收 入比上 | 营业成 本比上 | 毛利率比 | | 分行业 | 营业收入 | 营业成本 | （%） | 年同期 增减（%） | 年同期 增减 （%） | 上年同期 增减（%） | | 零售 | 5, ...

Group 1: Company Performance - In 2024, the company achieved revenue of 18 billion CNY, a year-on-year increase of 3.57% [3] - Net profit attributable to shareholders was 114 million CNY, a decline of 79.23% year-on-year [3] - Total assets amounted to 16.8 billion CNY, with a net asset scale of 7.6 billion CNY [3] - In Q1 2025, revenue was 4.767 billion CNY, a decrease of 6.53% year-on-year, and net profit was 160 million CNY, down 33.83% [3] Group 2: Store Operations - As of December 31, 2024, the number of stores reached 11,498, up from 10,255 at the beginning of the year [6] - In 2025 Q1, the net number of stores decreased by 47, totaling 11,451 stores [6] - The company plans to enhance the operational quality of existing stores rather than focusing on new openings [6] Group 3: Business Development - Retail business aims to reduce reliance on medical insurance payments, targeting a decrease from 30% to below 25% [7] - The company plans to increase the number of traditional Chinese medicine products from 350 to an additional 100 [7] - The medical and health business includes light diagnosis clinics and health management centers [7] Group 4: Market Environment - The consumption market has changed significantly, affecting product demand due to various factors including online and offline dynamics [8] - The industry is experiencing intense competition, with a rapid increase in the number of pharmacies leading to lower per-store output [9] - Regulatory changes may provide consolidation opportunities for leading chain enterprises like Yixin Tang [10] Group 5: Investment and Projects - In 2024, the company repurchased 10,401,300 shares for a total of approximately 134.71 million CNY [11] - Major capital expenditures in 2025 include investments in digitalization and logistics [11] Group 6: Digitalization - The company has implemented cloud services for various operational aspects, enhancing efficiency [12] - Digital applications include customer service, product management, and supply chain tracking [12] Group 7: Medical Insurance Policies - Medical insurance payments currently account for about one-third of total revenue [13] - The company anticipates opportunities for integration and optimization due to stricter medical insurance approvals [15] Group 8: Dividend Distribution - The proposed profit distribution for 2024 is 3 CNY per 10 shares, with a total cash dividend of approximately 172 million CNY [4][19]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [3][11]. Core Insights - The company reported a revenue of 26.497 billion RMB in 2024, reflecting an 8.0% year-on-year growth, while the net profit attributable to shareholders decreased by 21.6% to 915 million RMB [2]. - In Q1 2025, the company achieved a revenue of 6.956 billion RMB, a 3.0% increase year-on-year, with a net profit of 460 million RMB, up 15.5% year-on-year [2]. - The company is in a period of adjustment, optimizing its store network, which is expected to lead to stable profit growth post-adjustment [3]. Summary by Sections Performance Review - In 2024, the company achieved a total revenue of 26.497 billion RMB, with a net profit of 915 million RMB, and a non-recurring net profit of 885 million RMB, both showing declines compared to the previous year [2]. - For Q1 2025, the company reported a revenue of 6.956 billion RMB and a net profit of 460 million RMB, indicating a positive trend in profitability [2]. Operational Analysis - The company opened 907 self-built stores, acquired 420 stores, and added 1,885 franchise stores in 2024, while closing 733 stores to optimize its network [3]. - In Q1 2025, the company added 69 stores, including 54 new openings and 189 franchise stores, while closing 174 stores, resulting in a total of 16,622 stores [3]. - The fastest-growing segment in Q1 2025 was the Chinese and Western medicine category, generating approximately 5.32 billion RMB in revenue, a 5.8% increase year-on-year [3]. Profit Forecast, Valuation, and Rating - The company is expected to gradually return to normal growth after the adjustment period, with projected net profits of 1.1 billion RMB, 1.32 billion RMB, and 1.52 billion RMB for 2025, 2026, and 2027, respectively, representing year-on-year growth rates of 20.1%, 19.8%, and 15.3% [3]. - The estimated earnings per share (EPS) for 2025, 2026, and 2027 are 0.96 RMB, 1.16 RMB, and 1.33 RMB, with corresponding price-to-earnings (P/E) ratios of 17, 15, and 13 times [3].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [3][11]. Core Views - The company reported a revenue of 26.497 billion RMB in 2024, an increase of 8.0% year-on-year, but a decline in net profit attributable to shareholders by 21.6% to 915 million RMB [2]. - In Q1 2025, the company achieved a revenue of 6.956 billion RMB, a 3.0% increase year-on-year, with a net profit of 460 million RMB, reflecting a 15.5% increase [2]. - The company is undergoing a period of adjustment, optimizing its store network, which is expected to lead to stable profit growth post-adjustment [3]. Summary by Sections Performance Review - In 2024, the company achieved a total revenue of 26.497 billion RMB, with a net profit of 915 million RMB, and a non-recurring net profit of 885 million RMB, both showing declines compared to the previous year [2]. - For Q1 2025, the company reported a revenue of 6.956 billion RMB and a net profit of 460 million RMB, indicating positive growth in profitability [2]. Operational Analysis - The company opened 907 self-built stores, acquired 420 stores, and added 1,885 franchise stores in 2024, while closing 733 stores to optimize its network [3]. - In Q1 2025, the company net added 69 stores, with 54 new openings and 189 franchise additions, while closing 174 stores [3]. - The fastest-growing segment in Q1 2025 was traditional Chinese and Western medicine, generating approximately 5.32 billion RMB in revenue, a 5.8% increase year-on-year [3]. Profit Forecast, Valuation, and Rating - The company is expected to gradually return to normal growth after the adjustment period, with projected net profits of 1.1 billion RMB, 1.32 billion RMB, and 1.52 billion RMB for 2025, 2026, and 2027, respectively, reflecting year-on-year growth rates of 20.1%, 19.8%, and 15.3% [3]. - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 0.96 RMB, 1.16 RMB, and 1.33 RMB, with corresponding price-to-earnings (P/E) ratios of 17, 15, and 13 times [3].

Core Viewpoint - The pharmaceutical retail industry is undergoing significant adjustments, with major players like Guoyao Yizhi experiencing declines in revenue and profit due to increased competition and the impact of e-commerce [2][3]. Company Summary - Guoyao Yizhi reported a substantial decline in net profit for the year 2024, primarily due to challenges faced by its retail segment, Guoda Pharmacy, which closed 1,273 direct stores and 389 franchise stores, reducing its total store count to 9,569 [2]. - The gross margin of Guoyao Yizhi's retail business decreased from 25.08% in 2022 to 22.95% in 2024, indicating a downward trend despite previous expansions [2]. - The company acknowledged that the industry is in a deep adjustment phase, facing challenges such as declining customer traffic and increased store closures [2]. Industry Summary - The retail pharmacy sector is experiencing a slowdown in store expansion, with companies like Laobaixing, Jianzhijia, and Yixintang also reducing their expansion plans [2]. - According to data from Zhongkang Pharmacy, the total number of pharmacies in China reached 700,881 by the fourth quarter of 2024, marking a 2.3% year-on-year increase but a 0.5% quarter-on-quarter decline, indicating the first negative growth in recent years [3]. - The total number of store closures in 2024 was 39,228, resulting in a closure rate of approximately 5.76%, up from 3.8% in 2023, highlighting an accelerating trend of store closures [3]. - The retail drug market is projected to experience overall negative growth in 2024, with only slight growth in specific drug categories, driven by stricter regulatory requirements and increased competition from e-commerce [3].

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2][50]. Core Viewpoints - The FDA's recent decision to gradually eliminate animal testing requirements for monoclonal antibodies and other drugs is expected to benefit AI-driven drug development, potentially accelerating new drug approvals and reducing R&D costs [5][6][14][16]. - The pharmaceutical and biotechnology sector experienced a decline of 5.61% this week, underperforming the CSI 300 index by 2.73 percentage points, ranking 22nd among 31 sub-industries [19][24]. Summary by Sections Weekly Insights - The FDA's announcement on April 11, 2025, aims to replace animal testing with more effective and human-relevant methods, which could enhance drug safety and lower costs [14][15]. - The shift is anticipated to accelerate drug development timelines and improve success rates, particularly benefiting companies involved in AI drug development such as Jingtai Holdings and Chengdu Xian Dao [6][17]. Subsector Performance - The blood products sector saw the highest increase this week, rising by 4.06%, while the medical outsourcing sector faced the largest decline at 16.04% [7][23]. - The medical device sector decreased by 2.62%, and the traditional Chinese medicine sector fell by 3.35% [7][23]. Recommended and Benefiting Stocks - Recommended stocks include Weidian Physiotherapy, Maipu Medical, and Yingke Medical [8][31]. - Benefiting stocks from the FDA policy change include Jingtai Holdings, Chengdu Xian Dao, and Hongbo Pharmaceutical [6][17]. Detailed Subsector Analysis - **Medical Devices**: The sector is expected to benefit from the "old-for-new" policy and increased procurement activities in Q2 2025, with a current P/E ratio of 32.15, indicating potential for valuation growth [27][29]. - **Medical Consumables**: This sector is under pressure due to US-China tariff impacts, but certain segments are expected to perform well due to high growth potential and improved conditions [30]. - **IVD Sector**: The IVD sector is projected to recover as AI technologies enhance diagnostic capabilities, despite current pressures from procurement policies [33]. - **Blood Products**: The sector is expected to benefit from rising domestic production and increased focus on local sourcing due to tariff impacts [35]. - **Retail Pharmacy**: The offline pharmacy sector is seeing a recovery in customer traffic and profitability, with major players expected to leverage AI for operational efficiency [37][38].